Evofem Biosciences, INC. (EVFM) — 10-Q Filings

10-Q Filings (6)

• Evofem Narrows Q3 Loss Amidst Sales Dip, Royalty Gain Boosts Bottom Line — Nov 13, 2025 Risk: high
  Evofem Biosciences, Inc. reported a net loss of $1.569 million for the three months ended September 30, 2025, an improvement from a net loss of $2.365 million i
• Evofem Narrows Losses Amidst Sales Dip, Going Concern Looms — Aug 14, 2025 Risk: high
  Evofem Biosciences, Inc. reported a net loss of $828,000 for the six months ended June 30, 2025, a significant improvement from the $3.458 million net loss in t
• Evofem Biosciences Files Q1 2025 10-Q — May 15, 2025 Risk: medium
  Evofem Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first qua
• Evofem Biosciences Files Q3 2024 10-Q — Nov 14, 2024 Risk: medium
  Evofem Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results for the third quarter of 2024, detailin
• Evofem Biosciences Files Q2 2024 10-Q — Aug 14, 2024 Risk: medium
  Evofem Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business ope
• Evofem Biosciences, Inc. Files 10-Q for Period Ending March 31, 2024 — May 15, 2024 Risk:
  Evofem Biosciences, Inc. (EVFM) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Evofem Biosciences, Inc. filed a 10-Q report for the period ending

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX